Investigating the effect of zinc nanoparticles on the transmission of HPV infection

Investigating the effect of zinc nanoparticles on the transmission of HPV infection from a person infected with HPV virus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190624043991N21

Enrollment

Registered

2023-11-12

Start date

2024-03-05

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genital warts in the genitals of men. Anogenital (venereal) warts

Interventions

Intervention 1: Intervention group: Sample of human papillomavirus, 5 minutes after using the ointment containing zinc oxide nanoparticles, 25% (every 100 grams contains 25 groups of drugs), Bonyakhte

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Men in the age range of 18 to 60 years who have prominent genital warts Obtaining informed consent from patients

Exclusion criteria

Exclusion criteria: Men who have received the Gardasil vaccine according to the previous indications

Design outcomes

Primary

Measure	Time frame
The use of zinc oxide nanoparticles on HPV transmission. Timepoint: Before and 5 minutes after topical application of the ointment. Method of measurement: Molecular diagnosis laboratory (Real Time PCR ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Akram Mirzaei

Tehran University of Medical Sciences

mirzaee.scholar@gmail.com+98 21 6634 8560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026